Azelis reported a 3.2% increase in revenue for the first half of 2026, according to a brief statement carried by Investing.com on July 30. The headline figure offers a first glimpse of the specialty chemicals distributor’s performance, yet the announcement stops there—no segment splits, no margin data, and no commentary on what drove the expansion.
The absence of granularity matters because Azelis operates across two distinct business lines: Life Sciences and Industrial Chemicals. In the first quarter of 2026, the company disclosed that revenue fell 5.2% on a reported basis, with organic revenue down 3.9% and acquisitions contributing 3.3%. Life Sciences revenue was stable in constant currency, while the Industrial Chemicals segment faced headwinds. The H1 growth number therefore suggests a meaningful sequential improvement in the second quarter, but without a breakdown, investors cannot tell whether the recovery was broad-based or concentrated in one division.
Historical context adds texture. Azelis ended 2025 with audited financials and a clean audit opinion from PwC. During that year, it completed three bolt-on acquisitions—Distona in Switzerland, S. Amit Speciality Chemicals in India, and Solchem in Spain—extending its laboratory network that now serves over 65,000 customers. The company’s acquisition strategy has historically padded reported revenue, and the Q1 2026 figures showed a 3.3% contribution from deals. Whether the H1 3.2% growth includes a similar inorganic lift is unknown, but it is a variable that could flatter the organic trend.